Noted the same activity ,,, remember it's only a current SH that can sell down,,, you have to own them to sell them .. I'll be interested in monitoring the effort the company place on promotion of the 2nd set of Phase II 5505 Interim Data...
Many know my interest lays in the Skin Scarring reduction Treatment
Syntara believes that SNT-9465, the next-generation drug compound in an optimised formulation will allow daily dosing and should produce both cosmetic and physical improvements in a wide range of scar types. Following extensive discussions with clinicians worldwide regarding the unmet needs in scar treatment, it is evident that a significant commercial opportunity exists in modifying hypertrophic scars. Current standard of care, which includes costly laser therapy or painful steroid injections, requires multiple treatments to produce small incremental improvements. A daily topical treatment with SNT-9465 has the potential to provide profound patient benefits that can be effective without the need for repeat clinical visits. In parallel, the UWA scarring program under the leadership of Professor Fiona Wood will focus on keloid scars, which differ biologically from hypertrophic scars and present unique challenges for patients. Syntara will support an exploratory clinical trial set to begin in the second quarter of 2025
Fiona Wood Foundation commented: “Our long-term collaboration with Syntara illustrates the benefits of academia and industry working hand in hand. We are pushing ahead with exploratory research with the first generation SNT-6302 in keloids where we need a better understanding of the underlying pathophysiology whilst Syntara drives the next generation SNT-9465 through the clinical and regulatory steps necessary to potentially change the standard of care in scar treatment.”
That's it for me , Weekend has arrived early,, Best of Luck to all Invested ,,NZT
Expand
